002898.Sz
The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products.
Business. The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products.
The company maintains a debt-to-equity ratio of 0.5, indicating a relatively balanced capital structure with a moderate reliance on debt financing. Its liquidity position is assessed as medium, with operating cash flow of 19,058,540 CNY and capital expenditure of -23,352,700 CNY, suggesting that the company is investing in its operations while maintaining a modest cash flow. The company's net cash position is negative after subtracting total debt, which may pose some liquidity risk.
In terms of profitability, the company reported a revenue of 518,763,270 CNY, with a total equity of 380,149,510 CNY. The company's operating cash flow is positive, but its capital expenditure is negative, indicating that the company is investing in its operations. The company's profitability metrics should be compared against the industry median to assess its relative performance.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This concentration may expose the company to higher risk if the segment faces challenges or if the market for its products declines.
The company's growth trajectory is reflected in its revenue of 518,763,270 CNY. The company's capital expenditure of -23,352,700 CNY suggests that it is investing in its operations, which may support future growth. However, the company's liquidity position is a concern, as its net cash is negative after subtracting total debt.
The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which may affect its ability to meet short-term obligations. The company's dilution risk is low, suggesting that there is little immediate threat to shareholder value from new share issuances.
Recent events and filings have not been disclosed in the provided data. The company's financial performance and risk profile should be monitored for any changes that may affect its operations and financial stability.
- The company has a balanced capital structure with a debt-to-equity ratio of 0.5.
- The company's liquidity position is medium, with a negative net cash position after subtracting total debt.
- The company's revenue is concentrated in a single business segment, which may increase its risk exposure.
- The company is investing in its operations, as indicated by its capital expenditure of -23,352,700 CNY.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- 002898.SZ Market data — financials · 2026-05-26
- Sailong Pharmaceutical Group Co Ltd Market data — analyst estimates · 2026-05-26
Ownership & reference
Insider activity
Short positioning
Geographic breakdown
Intel & risk
4 tracked-field change(s) detected vs prior analysis; max severity: medium.
- Dilution risk— → lowlow
- Liquidity risk— → mediumlow
- Activity— → Pharmaceuticals & Medical Researchmedium
- Economic sector— → Healthcaremedium